Duck viral hepatitis (DVH) is an acute, highly contagious disease that affects newly hatched ducklings less than 3 weeks old. Duck hepatitis A virus (DHAV), a member of the genus Avihepatovirus, of the family Picornaviridae, is the most reported disease-causing agent. DHAVs are clustered into three distinct genotypes/serotypes, that is, DHAV-1, DHAV-2, and DHAV-3. DHAV-1 is distributed worldwide; however, DHAV-2 is reported only in Taiwan and India. In addition, DHAV-3 is identified in South Korea, Vietnam, China, and Egypt. DHAVs are neither identified as zoonotic agents nor associated with public health significance. Meanwhile, the disease is responsible for tremendous economic losses for the duck farming industry due to the high mortality rates. The disease is characterized by a characteristic disease pattern, clinical signs, and gross lesions; however, the DHAVs cannot be distinguished based only on clinical observations and pathological findings. The causative agents can be isolated and identified by isolation into embryonated chicken or duck eggs, cell culture systems, or by reproducing the disease in susceptible ducklings. The disease-causative agent can also be identified by nucleic acid amplification techniques (NAT), that is, reverse transcription polymerase chain reaction (RT-PCR) approaches. There is no specific treatment for infection with DVH. Vaccination has been used as a preventive measure and for controlling disease outbreaks. Live-attenuated vaccines are being used for active and passive immunization of susceptible duck flocks; meanwhile, inactivated vaccines are administered to breeder ducks to elicit persistent, homogenous, and protective levels of maternal-derived antibodies (MDA) in their offspring.